BEIJING, March 8 (Xinhua) — Danish pharmaceutical giant Novo Nordisk is planing slew of alliances with Chinese startups, universities and research institutions, China Daily reported Friday.
Danish pharmaceutical giant Novo Nordisk has launched a platform called “Innovo” to further enhance its innovation capabilities in China through alliances with local universities and hospitals, pharmaceutical startups, and incubators.
The company aims to build through the program an open, integrated, efficient and collaborative research and development ecosystem to accelerate the transformation of scientific research into innovative drug discovery and development.
The “Innovo” platform is based on Novo Nordisk’s strategy of “Partnering for Innovation in China and will enhance the company’s global research and development,” according to the report.
During the next three to five years, the company hopes to incubate three to five “mature projects” through the program, aiming to result in new drug pipelines.